Diuretics are among the most frequently prescribed drugs in clinical medicine, with applications spanning acute decompensated heart failure, hypertension, nephrolithiasis, hypercalcemia, and the complex fluid management problems of cirrhosis and nephrotic syndrome. Understanding diuretic pharmacology requires a working knowledge of the renal tubular transport machinery that each class targets, because the selectivity of tubular action determines not only the natriuretic potency of each drug but also the specific electrolyte consequences that follow sustained use. This module covers loop diuretics and thiazides, the two most clinically important classes, with emphasis on mechanism, pharmacokinetics, electrolyte physiology, key trial evidence, drug interactions, and the management of diuretic resistance.
The nephron reabsorbs approximately 99% of the 180 liters of glomerular filtrate produced daily, distributed unevenly across four tubular segments, each with its own transporter machinery. The proximal convoluted tubule (PCT) accounts for roughly 65% of sodium reabsorption, driven primarily by the sodium-hydrogen exchanger isoform 3 (NHE3) on the luminal surface, working in concert with carbonic anhydrase (CA) to facilitate coupled sodium and bicarbonate absorption. Carbonic anhydrase inhibitors act here, though this site is not the primary target of loop diuretics or thiazides.
The thick ascending limb (TAL) of the loop of Henle reabsorbs approximately 25% of filtered sodium via the Na-K-2Cl cotransporter isoform 2 (NKCC2), and this segment is impermeable to water. Water cannot follow the sodium being pumped out, which means NKCC2-mediated reabsorption is essential for generating the hypertonic medullary interstitium required for antidiuretic hormone (ADH)-dependent urinary concentration. When NKCC2 is blocked by loop diuretics, the medullary gradient is disrupted and a large volume of isotonic tubular fluid is delivered to more distal segments, generating the most potent natriuresis achievable with any diuretic class.
The distal convoluted tubule (DCT) handles approximately 5–8% of filtered sodium through the electroneutral Na-Cl cotransporter (NCC), the target of thiazide diuretics. Because the DCT is permeable to water in the absence of ADH stimulation, NCC blockade produces a more modest natriuresis than NKCC2 blockade, but it is well suited for sustained outpatient use. The collecting duct (CD) accounts for only 2–3% of sodium reabsorption via the epithelial sodium channel (ENaC), regulated by aldosterone and targeted by potassium-sparing diuretics. Understanding the fractional sodium delivery at each segment is essential for predicting both the potency and the ceiling effect of each diuretic class.1,2
Loop diuretics produce their natriuretic effect by binding to the chloride-binding site on the Na-K-2Cl cotransporter isoform 2 (NKCC2) from the luminal side of the thick ascending limb (TAL), inhibiting the coupled entry of one sodium, one potassium, and two chloride ions per transport cycle. By abolishing the lumen-positive electrical potential that normally drives paracellular reabsorption of divalent cations in the TAL, loop diuretics also promote urinary losses of calcium (calciuresis) and magnesium (magnesiuresis).2 This calciuric effect distinguishes loop diuretics from thiazides and has direct clinical utility in the management of hypercalcemia, while the magnesiuric effect contributes to a clinically significant hypomagnesemia that can render hypokalemia refractory to potassium supplementation alone.
Loop diuretics reach the tubular lumen not by glomerular filtration but by active secretion via organic anion transporters (OAT) located in the proximal tubular basolateral membrane. In chronic kidney disease (CKD), competing endogenous and exogenous organic anions accumulate in plasma and compete for OAT binding, reducing tubular secretion of loop diuretics and attenuating the luminal drug concentration achievable at therapeutic doses.1 ENaC (epithelial sodium channel) regulation in the collecting duct also modulates the natriuretic response: in patients with hypoalbuminemia, the natriuretic response per unit of luminal drug concentration is reduced because tubular fluid contains excess albumin that can bind and inactivate the drug at its luminal site of action.3
Furosemide is the most widely used loop diuretic but also the most pharmacokinetically variable, with oral bioavailability ranging from 10% to 90% across patients, a half-life of approximately 1.5–2 hours, and roughly 65% renal clearance via tubular secretion. This variability explains the clinical unpredictability of oral furosemide in hospitalized patients with bowel wall edema, which impairs absorption. Torsemide has superior oral bioavailability of 80–90%, a longer half-life of 3–4 hours, and predominantly hepatic metabolism (approximately 80%), making its pharmacokinetics more predictable in renal impairment. The TRANSFORM-HF (Torsemide Comparison With Furosemide for Management of Heart Failure) trial found no significant difference in all-cause mortality between torsemide and furosemide at one year, though secondary outcomes marginally favored torsemide.6
Bumetanide is approximately 40 times as potent as furosemide on a milligram basis, with superior and more consistent oral bioavailability. It targets the Na-K-2Cl cotransporter isoform 1 (NKCC1) in the inner ear, as does furosemide, contributing to dose-dependent ototoxicity. Ethacrynic acid is the only loop diuretic that is not a sulfonamide derivative, which gives it a niche in patients with true sulfonamide hypersensitivity. It carries the highest ototoxic risk of the class and is used sparingly. The ototoxicity of loop diuretics, manifesting primarily as high-frequency sensorineural hearing loss, is amplified by concurrent aminoglycoside use, an additive toxic interaction of practical significance in the inpatient setting.4
Loop diuretics exhibit a sigmoidal dose-response relationship: below a threshold luminal concentration there is no natriuresis, above that threshold the response rises steeply, and above a ceiling concentration there is no additional natriuresis regardless of dose increase. In CKD, the dose required to reach threshold is higher and the plateau is lower. The appropriate clinical response is dose escalation to reach threshold, not dose increase beyond the ceiling. In patients who fail to respond to escalation, sequential nephron blockade with a thiazide-like agent such as metolazone is the next maneuver.
Thiazides and thiazide-like diuretics inhibit the Na-Cl cotransporter (NCC) in the distal convoluted tubule (DCT) by binding to the chloride-binding pocket of the transporter from the luminal surface. Because NCC transport is electroneutral, NCC blockade does not generate a lumen-positive potential, and paracellular calcium reabsorption is not impaired as it is in the thick ascending limb (TAL). In fact, NCC blockade has the opposite effect on calcium: by reducing intracellular sodium in the DCT cell, it enhances basolateral sodium-calcium exchange via the Na-Ca exchanger isoform 1 (NCX1), increasing calcium entry from the tubular lumen through the apical calcium channel TRPV5 (transient receptor potential vanilloid 5). The net result is calcium retention rather than calciuresis, giving thiazides a calcium-sparing effect opposite to that of loop diuretics.2
Chlorthalidone is a thiazide-like agent with a half-life of 40–60 hours, compared with 6–15 hours for hydrochlorothiazide (HCTZ). This pharmacokinetic difference is clinically meaningful: chlorthalidone provides more consistent 24-hour blood pressure control, and the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) demonstrated that chlorthalidone-based therapy reduced cardiovascular events more effectively than amlodipine or lisinopril-based therapy in high-risk hypertensive patients, making it a guideline-preferred agent for hypertension.8 Indapamide is another thiazide-like agent with a modest vasodilatory effect at low doses mediated by calcium channel antagonism in vascular smooth muscle. The ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) trial demonstrated that fixed-dose perindopril plus indapamide reduced macrovascular and microvascular events in type 2 diabetes.9
Metolazone retains diuretic efficacy at glomerular filtration rates (GFR) below 30 mL/min/1.73 m2, where conventional thiazides and HCTZ lose effectiveness. This is attributed in part to a proximal tubular action of metolazone that augments its distal NCC blockade. In clinical practice, metolazone is used almost exclusively as an add-on agent to loop diuretics in loop-resistant volume overload, exploiting sequential nephron blockade. The combination can produce dramatic natriuresis and should be accompanied by electrolyte and renal function monitoring within 24–48 hours of initiation.1
Loop diuretics increase urinary calcium via the TAL lumen-positive potential: useful in hypercalcemia, contraindicated in calcium nephrolithiasis. Thiazides decrease urinary calcium via TRPV5-mediated DCT retention: contraindicated in hypercalcemia, beneficial in calcium nephrolithiasis, reducing stone recurrence by 30–50%. This calcium divergence is a direct consequence of the different tubular segments targeted by each class.
Hypokalemia is the most common electrolyte complication of both loop and thiazide diuretics, though the mechanisms differ. Loop diuretics block Na-K-2Cl cotransporter isoform 2 (NKCC2)-mediated potassium reabsorption in the thick ascending limb (TAL) and simultaneously increase flow and sodium delivery to the collecting duct (CD), where the increased luminal sodium concentration stimulates epithelial sodium channel (ENaC)-mediated sodium absorption. This creates a more lumen-negative potential in the CD, driving potassium secretion via the renal outer medullary potassium channel (ROMK) and proton secretion from the alpha-intercalated cells. Thiazides generate hypokalemia by a different pathway: Na-Cl cotransporter (NCC) blockade triggers volume-mediated secondary hyperaldosteronism, which upregulates ENaC and ROMK and drives kaliuresis independently of the primary NCC blockade.2,3
Hypomagnesemia accompanies hypokalemia and must be recognized as a pharmacological problem in its own right. In the TAL, loop diuretics abolish the lumen-positive potential that normally drives paracellular magnesium reabsorption. In the distal convoluted tubule (DCT), thiazide-mediated NCC blockade downregulates the epithelial magnesium channel TRPM6 (transient receptor potential melastatin 6), impairing active magnesium reabsorption. The clinical consequence is that when magnesium is depleted, ROMK-mediated potassium secretion in the CD cannot be adequately suppressed, and hypokalemia becomes refractory to potassium replacement alone. Concurrent magnesium repletion is required before potassium levels will normalize.2
Hyponatremia is more common and more dangerous with thiazides than with loop diuretics because thiazides impair urinary dilution without impairing urinary concentration. Loop diuretics disrupt the medullary concentration gradient, producing a urine that is isotonic or near-isotonic regardless of antidiuretic hormone (ADH) status. Thiazides, acting only in the DCT, impair dilution but leave the medullary gradient intact, so patients can still respond to ADH with highly concentrated urine. In a patient with non-osmotic ADH secretion caused by pain, nausea, or volume depletion, this combination is the substrate for profound hyponatremia. Elderly women on thiazides represent the classic at-risk group.10
Metabolic alkalosis develops with sustained loop or thiazide therapy through three reinforcing mechanisms: angiotensin II-driven sodium-hydrogen exchanger isoform 3 (NHE3) upregulation in the proximal convoluted tubule (PCT) increases bicarbonate reabsorption; hypokalemia drives cellular hydrogen-potassium exchange that raises extracellular bicarbonate; and secondary aldosteronism increases proton secretion in the alpha-intercalated cells of the CD. Hyperuricemia occurs because loop and thiazide diuretics compete with urate at organic anion transporter (OAT) sites in the PCT, reducing urate secretion, and volume contraction upregulates the urate-anion exchanger URAT1 (urate transporter 1), increasing proximal reabsorption.4 Glucose intolerance is more pronounced with thiazides than loop diuretics and has been linked mechanistically to hypokalemia impairing beta-cell membrane potential and reducing insulin secretion, confirmed in a pooled quantitative review of trial data.11
In heart failure with reduced ejection fraction (HFrEF), loop diuretics are the standard of care for symptomatic volume overload, with intravenous (IV) furosemide providing faster and more reliable natriuresis than oral therapy in acute decompensated heart failure (ADHF). The DOSE (Diuretic Optimization Strategies Evaluation) trial established that high-dose IV furosemide at 2.5 times the total oral daily dose was not inferior to low-dose furosemide and produced greater net fluid loss and more rapid symptom relief, supporting dose escalation rather than conservative dosing in the acute setting.5 The STRONG-HF (Safety, Tolerability and Efficacy of Up-Titration of Guideline-Directed Medical Therapies for Acute Heart Failure) trial reinforced the value of aggressive early optimization of evidence-based heart failure therapies, with high-intensity management reducing 180-day readmission and death compared with usual care.12
In hypertension, chlorthalidone is the preferred thiazide-class agent based on ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) outcome data, demonstrating superiority over lisinopril in reducing stroke and over amlodipine in reducing heart failure hospitalization in the highest-risk subgroups.8 In patients with resistant hypertension, the PATHWAY-2 (Prevention and Treatment of Hypertension With Algorithm-Based Therapy 2) trial demonstrated that spironolactone added as a fourth agent outperformed both bisoprolol and doxazosin in reducing blood pressure, establishing mineralocorticoid receptor antagonism as the preferred fourth-line add-on strategy in true resistant hypertension.
In hypercalcemia, the standard acute management is aggressive IV saline to restore intravascular volume and promote calciuresis, followed by loop diuretics to sustain calcium excretion once intravascular volume is repleted. Thiazides are absolutely contraindicated in hypercalcemia because they reduce urinary calcium and would worsen the condition. In calcium oxalate and calcium phosphate nephrolithiasis, thiazides reduce urinary calcium by 30–50% through transient receptor potential vanilloid 5 (TRPV5)-mediated calcium retention in the distal convoluted tubule (DCT) and are a first-line pharmacological intervention for stone recurrence prevention, as confirmed in a systematic review and meta-analysis of randomized trials.7 Patients on thiazides for nephrolithiasis should maintain high fluid intake, as the stone-protective benefit depends on high urine volume in addition to reduced urinary calcium concentration.
Nonsteroidal anti-inflammatory drugs (NSAIDs) attenuate the natriuretic response to both loop and thiazide diuretics by inhibiting cyclooxygenase (COX)-dependent prostaglandin synthesis in the kidney. Renal prostaglandins, particularly prostaglandin E2 (PGE2) and prostacyclin (PGI2), normally oppose tubular sodium reabsorption and maintain glomerular filtration rate (GFR) by dilating the afferent arteriole. COX inhibition removes this vasodilatory and natriuretic tone, reducing GFR and blunting the diuretic response. In patients with heart failure with reduced ejection fraction (HFrEF) or chronic kidney disease (CKD) who depend on prostaglandin-mediated GFR maintenance, concurrent use of these agents can precipitate acute kidney injury (AKI) and markedly diminish the efficacy of diuretic therapy. This interaction is clinically significant and frequently overlooked in patients who self-medicate with over-the-counter nonsteroidal anti-inflammatory drugs.1,4
Aminoglycosides potentiate loop diuretic ototoxicity through additive cochlear hair cell damage, and the combination should be used with close audiological monitoring when clinically necessary. Lithium toxicity is a well-established consequence of loop and thiazide diuretic use in patients taking lithium for mood stabilization. Both diuretic classes reduce plasma sodium, triggering compensatory upregulation of sodium-hydrogen exchanger isoform 3 (NHE3)-mediated sodium and lithium reabsorption in the proximal convoluted tubule (PCT). Thiazides in particular can double or triple lithium plasma concentrations within days of initiation. When a diuretic is required in a lithium-treated patient, amiloride is the preferred agent because it does not promote proximal lithium reabsorption.4
Digoxin toxicity risk is amplified by diuretic-induced hypokalemia and hypomagnesemia. Potassium and magnesium compete with digoxin for binding to the alpha-subunit of Na/K-ATPase; when both cations are depleted, digoxin binding affinity increases and its toxic threshold falls. A patient clinically stable on a fixed digoxin dose can develop toxicity rapidly after a diuretic-induced electrolyte shift, making routine potassium and magnesium monitoring mandatory in patients receiving both drug classes.4
Diuretic resistance, defined as an inadequate natriuretic response despite appropriate dosing, arises through multiple parallel mechanisms. In the acute setting, bowel wall edema impairs oral furosemide absorption, making the already-low bioavailability (10–90%) even less predictable; switching to IV administration reliably overcomes this barrier. In chronic kidney disease (CKD), competing endogenous organic anions occupy organic anion transporter (OAT) sites and reduce luminal delivery of the diuretic below the threshold concentration needed for Na-K-2Cl cotransporter isoform 2 (NKCC2) blockade; dose escalation is required to saturate OAT competition and restore adequate luminal drug concentration.1,3
Post-diuretic sodium avidity is a physiological counterregulatory phenomenon: as the acute diuretic effect wanes, the kidney activates compensatory sodium reabsorption in all tubular segments, particularly the distal convoluted tubule (DCT) and collecting duct (CD), partially negating the prior natriuresis. With chronic loop diuretic use, DCT cells and CD principal cells hypertrophy in response to chronically elevated sodium and fluid delivery, upregulating Na-Cl cotransporter (NCC) and ENaC expression and creating a structural compensatory capacity that further blunts the loop diuretic response. This neurohormonal and structural adaptation is the rationale for sequential nephron blockade: adding a thiazide or thiazide-like agent (most commonly metolazone) to block NCC simultaneously with NKCC2 blockade prevents DCT-mediated compensatory sodium reabsorption. Hypoalbuminemia contributes to resistance by binding furosemide in the tubular lumen, reducing the free drug concentration available to inhibit NKCC2.1
A practical approach to diuretic resistance begins with IV conversion and dose escalation to overcome the threshold effect and OAT competition. If response remains inadequate, frequency of dosing should be increased before dose is further escalated, since the post-diuretic sodium avidity period represents a pharmacodynamic dead zone between doses. Serum potassium, magnesium, and creatinine should be rechecked within 24–48 hours of any regimen change. Concurrent nephrotoxin exposure (nonsteroidal anti-inflammatory drugs, contrast agents, aminoglycosides) should be eliminated. If escalation and frequency adjustments fail, sequential nephron blockade with metolazone 2.5–5 mg before the loop diuretic dose can produce dramatic additional natriuresis, but requires close electrolyte surveillance. Daily weight monitoring is essential to track net fluid balance response.1,5
Before labeling a patient diuretic-resistant, confirm: (1) adequate bioavailability — switch to IV if bowel edema is possible; (2) dose is above threshold, not merely above the prior dose; (3) dosing frequency matches the duration of action; (4) no concurrent NSAIDs, contrast agents, or aminoglycosides; (5) potassium and magnesium are repleted; (6) hypoalbuminemia has been considered as a pharmacokinetic barrier. Only after these steps should metolazone be added for sequential nephron blockade.
Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017;377(20):1964–1975.
doi:10.1056/NEJMra1703100Hoorn EJ, Ellison DH. Diuretic resistance. Am J Kidney Dis. 2017;69(1):136–142.
doi:10.1053/j.ajkd.2016.08.027Bhalla V, Hallows KR. Mechanisms of ENaC regulation and clinical implications. J Am Soc Nephrol. 2008;19(10):1845–1854.
doi:10.1681/ASN.2008020225Brater DC. Diuretic therapy. N Engl J Med. 1998;339(6):387–395.
doi:10.1056/NEJM199808063390607Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797–805.
doi:10.1056/NEJMoa1005419Mentz RJ, Anstrom KJ, Eisenstein EL, et al. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial. JAMA. 2023;329(3):214–223.
doi:10.1001/jama.2022.23861Fink HA, Akornor JW, Garimella PS, et al. Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials. Eur Urol. 2009;56(1):72–80.
doi:10.1016/j.eururo.2009.03.031ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288(23):2981–2997.
doi:10.1001/jama.288.23.2981Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial). Lancet. 2007;370(9590):829–840.
doi:10.1016/S0140-6736(07)61303-8Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008;52(1):144–153.
doi:10.1053/j.ajkd.2008.03.004Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006;48(2):219–224.
doi:10.1161/01.HYP.0000231552.10054.aaMebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938–1952.
doi:10.1016/S0140-6736(22)02076-1